MAPT and progressive supranuclear palsy: For instance, benfotiamine treatment has proven effective in exerting neuroprotective effects by activating the Nrf2/ARE pathway in a P301S mouse model of tauopathy, representing a promising therapeutic approach for diseases with tau pathology, such as AD, FTD, and progressive supranuclear palsy [81].